Unedited microneurosurgery of a posterior fossa pilocytic astrocytoma.
Conclusion: This unedited video offers all detailed aspects that are, as the senior author JH considers, essential for a neurosurgeon when performing an efficient and safe surgery for a large PA in the posterior fossa. Videolink: http://surgicalneurologyint.com/videogallery/cerebellar-tumor. PMID: 30595956 [PubMed]
Conclusion: We report a 33.9% positive yield, with 65.8% of patients undergoing further workup as a result of CE and 12.7% requiring therapeutic intervention. We conclude that CE plays an important role in the investigation of IDA and occult gastrointestinal bleeding and has important implications on further management.
Conclusions: This is an institution-based, detailed, and descriptive epidemiological study of patients with primary CNS tumors in Saudi Arabia. In contrast to other regional and international studies, the medulloblastomas in our institution are more frequent than pilocytic astrocytomas. Limitations to our study included the referral bias and histology-based methodology. PMID: 32256589 [PubMed]
Publication date: Available online 8 April 2020Source: Pharmacological ResearchAuthor(s): Federico Cucchiara, Francesco Pasqualetti, Filippo Sean Giorgi, Romano Danesi, Guido Bocci
Authors: Ying S, Liping Z, Zhulin G, Yanhong D, Liang G Abstract Background: Arm choice for peripherally inserted central catheter (PICC) insertion is often determined by PICC nurses.Objectives: To explore the impact of arm choice (dominant or non-dominant) on the rate of catheter-related complications and degree of comfort in patients with PICCs.Design: A cross-sectional study.Methods: We used questionnaires and scales to collect 255 patients' general information, catheter-related complications and comfort degree. They were divided into two groups (PICC inserted in the dominant or non-dominant arm).Results: There ...
Conclusion Dual antithrombotic and NOAC regimens have reduced bleeding without compromising the risk of cardiovascular events or mortality, and should be preferred for patients with ACS or PCI also needing long-term anticoagulation.
Conclusion Prolonged DAPT reduces cardiac mortality and major adverse cardiovascular events in complex PCI. The results would need confirmation in a larger randomized study.
Condition: Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Intervention: Drug: Dacomitinib Sponsor: Guangdong Association of Clinical Trials Not yet recruiting
In February, the manufacturer of the weight-loss medication lorcaserin (Belviq, Belviq XR) voluntarily withdrew the drug from the US market at the request of the FDA. This was a result of emerging data showing that people who had taken the drug as part of a large clinical trial had an increased occurrence of cancer five years later. What were the findings about Belviq, and why did this information come to light now? Lorcaserin was approved by the FDA in 2012. As part of the approval process, the FDA reviewed a series of clinical trials that looked at its effects on weight and its safety profile, compared to a placebo. Base...
Conclusion: In this small exploratory study, HTPR was frequent in PAD patients. Furthermore, the results are suggestive that MALE might be associated with dual HTPR. This leads to the hypothesis that optimized antithrombotic regimens post percutaneous transluminal angioplasty should be tested in clinical trials. PMID: 32252582 [PubMed - as supplied by publisher]
We’ve all heard scary inpatient stories from the psychiatric hospital. Perhaps you have a personal experience that you’d rather forget. In today’s podcast, Gabe asks a psychologist with 25 years of hospital experience the tough questions surrounding psych wards: Why do so many psychiatric inpatients seem to have such unpleasant — or even traumatizing — experiences while there? Are these stories the norm or the exception? For those who have had bad experiences, how can we change things? Tune in to hear the unique perspective of Dr. David Susman, a licensed clinical psychologist who offer...